GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70317 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von R Jajou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. Hauptthemen laut MEDLINE: Venous Thromboembolism, Primary Health Care, COVID-19 Vaccines, Referral and Consultation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Welfare and Sport.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Introduction
Venous thromboembolism (VTE) is labeled as an adverse effect of the adeno‐vector‐based vaccines AstraZeneca and Johnson & Johnson. We aimed to study whether there was an increase in general practitioner (GP) consultations for VTE after COVID‐19 vaccination.
Methods
An exposure‐anchored self‐controlled cohort study was performed among COVID‐19 vaccinated persons aged ≥ 12 years who were registered in the PHARMO Data Network and Nivel Primary Care Database in the Netherlands. The focal window was set at 28 days after each COVID‐19 vaccination and the referent window at all time outside the focal window. Adjusted incidence rate ratios (aIRR), adjusting for SARS‐CoV‐2 infection, were calculated using Poisson regression.
Results
In total, 2 133 853 persons were included. The highest increase in GP consultations for VTE was observed after Johnson & Johnson vaccination (aIRR: 3.14, 95% CI: 1.50–6.57), and a slight increase after Pfizer/BioNTech dose 1 (aIRR: 1.24, 95% CI: 1.09–1.40). Risk groups were 12–60 year‐olds with increased GP consultations for VTE after Johnson & Johnson (aIRR: 2.30, 95% CI: 1.44–3.69) and Pfizer/BioNTech (aIRR: 1.29, 95% CI: 1.11–1.50), and in specific groups of males aged 12–60 years. Also, females using hormone‐containing contraceptives or hormone replacement therapy (HRT) showed increased GP consultations for VTE after AstraZeneca (aIRR: 2.87, 95% CI: 1.13–7.33) and Pfizer/BioNTech (aIRR: 1.48, 95% CI: 1.10–2.01).
Conclusion
Increased GP consultations for VTE were observed after both vector and mRNA vaccination, in particular among males, 12–60 year olds, and females using hormone‐containing contraceptives or HRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.
- Department of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, the Netherlands.
- Nivel (Netherlands Institute for Health Services Research), Utrecht, the Netherlands.
- PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: R Jajou, E P van Puijenbroek, K Hek, J A Overbeek, F P A M van Hunsel, A C Kant
Förderung
- Ministry of Health, Welfare and Sport
Zitieren
APA
Jajou, R., van Puijenbroek, E. P., Hek, K., Overbeek, J. A., van Hunsel, F. P. A. M., Mulder, E., & Kant, A. C. (2026). GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70317
Vancouver
Jajou R, van Puijenbroek EP, Hek K, Overbeek JA, van Hunsel FPAM, Mulder E, et al. GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70317
BibTeX
@article{Jajou2026,
author = {Jajou, R and van Puijenbroek, E P and Hek, K and Overbeek, J A and van Hunsel, F P A M and Mulder, Erik and Kant, A C},
title = {GP Consultations for Venous Thromboembolism ( VTE ) After mRNA and Adeno‐Vector‐Based COVID ‐19 Vaccination—An Exposure‐Anchored Self‐Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70317}
}
EUVIMED